Impact of Endotoxins in Gelatine Hydrogels on Chondrogenic Differentiation and Inflammatory Cytokine Secretion In Vitro.
Gelatine Methacryloyl (GelMA)
articular cartilage regeneration
inflammatory mediator
lipopolysaccharide (LPS)
mesenchymal stromal cell (MSC)
peripheral blood mononuclear cell (PBMC)
regenerative medicine
type A and type B gelatine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 Nov 2020
13 Nov 2020
Historique:
received:
06
10
2020
revised:
02
11
2020
accepted:
11
11
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
4
3
2021
Statut:
epublish
Résumé
Gelatine methacryloyl (GelMA) hydrogels are widely used in studies aimed at cartilage regeneration. However, the endotoxin content of commercially available GelMAs and gelatines used in these studies is often overlooked, even though endotoxins may influence several cellular functions. Moreover, regulations for clinical use of biomaterials dictate a stringent endotoxin limit. We determined the endotoxin level of five different GelMAs and evaluated the effect on the chondrogenic differentiation of equine mesenchymal stromal cells (MSCs). Cartilage-like matrix production was evaluated by biochemical assays and immunohistochemistry. Furthermore, equine peripheral blood mononuclear cells (PBMCs) were cultured on the hydrogels for 24 h, followed by the assessment of tumour necrosis factor (TNF)-α and C-C motif chemokine ligand (CCL)2 as inflammatory markers. The GelMAs were found to have widely varying endotoxin content (two with >1000 EU/mL and three with <10 EU/mL), however, this was not a critical factor determining in vitro cartilage-like matrix production of embedded MSCs. PBMCs did produce significantly higher TNF-α and CCL2 in response to the GelMA with the highest endotoxin level compared to the other GelMAs. Although limited effects on chondrogenic differentiation were found in this study, caution with the use of commercial hydrogels is warranted in the translation from in vitro to in vivo studies because of regulatory constraints and potential inflammatory effects of the content of these hydrogels.
Identifiants
pubmed: 33202964
pii: ijms21228571
doi: 10.3390/ijms21228571
pmc: PMC7696312
pii:
doi:
Substances chimiques
Cytokines
0
Endotoxins
0
Hydrogels
0
Gelatin
9000-70-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : European Research Council
ID : n°647426 (3D-JOINT)
Pays : International
Organisme : ReumaNederland
ID : LLP-12, LLP-22
Références
J Rheumatol. 1997 Feb;24(2):365-71
pubmed: 9034998
Nature. 1986 Aug 7-13;322(6079):547-9
pubmed: 3736671
Cancer Biother Radiopharm. 2002 Aug;17(4):371-7
pubmed: 12396701
Biomaterials. 2011 Jun;32(16):3921-30
pubmed: 21397942
Ann Rheum Dis. 2007 Jan;66(1):121-3
pubmed: 16740681
Connect Tissue Res. 2020 Mar;61(2):137-151
pubmed: 30526130
Adv Healthc Mater. 2019 Apr;8(7):e1800418
pubmed: 29911317
Cell Immunol. 2017 May;315:1-10
pubmed: 28284487
PLoS One. 2015 Jul 15;10(7):e0132781
pubmed: 26176237
Cancer Biother Radiopharm. 2001 Oct;16(5):431-7
pubmed: 11776760
J Comput Biol. 2005 Oct;12(8):1047-64
pubmed: 16241897
J Bone Miner Res. 2020 Jun 21;:
pubmed: 32564401
Genes Dev. 2003 Oct 1;17(19):2368-73
pubmed: 14522944
ACS Appl Mater Interfaces. 2019 Aug 28;11(34):30518-30533
pubmed: 31373791
Front Bioeng Biotechnol. 2018 Sep 19;6:116
pubmed: 30283776
Tissue Eng Part B Rev. 2016 Apr;22(2):149-59
pubmed: 26467024
Arthritis Rheum. 2002 Mar;46(3):704-13
pubmed: 11920406
Exp Cell Res. 2018 Sep 15;370(2):653-662
pubmed: 30036540
Stem Cells Dev. 2018 Nov 1;27(21):1518-1525
pubmed: 30044182
Osteoarthritis Cartilage. 2013 Aug;21(8):1116-24
pubmed: 23685224
Regen Ther. 2017 Sep 09;7:45-51
pubmed: 30271851
PLoS One. 2017 Jan 17;12(1):e0170312
pubmed: 28095466
PLoS One. 2015 May 01;10(5):e0124529
pubmed: 25933372
Yonsei Med J. 2015 Jul;56(4):1134-42
pubmed: 26069140
Biomacromolecules. 2000 Spring;1(1):31-8
pubmed: 11709840
Macromol Biosci. 2018 Dec;18(12):e1800168
pubmed: 30286274
Sci Rep. 2019 May 3;9(1):6863
pubmed: 31053756
Arthritis Rheumatol. 2015 Oct;67(10):2691-701
pubmed: 26138996
Ann Rheum Dis. 2017 May;76(5):914-922
pubmed: 27965260
Arthritis Res Ther. 2013;15(5):R111
pubmed: 24020912
PLoS One. 2013;8(2):e57683
pubmed: 23437402
Bone. 2016 Mar;84:262-270
pubmed: 26780388
Materials (Basel). 2016 Sep 24;9(10):
pubmed: 28773918
Acta Biomater. 2017 Oct 1;61:41-53
pubmed: 28782725
Biomaterials. 2010 Jul;31(21):5536-44
pubmed: 20417964
Nat Commun. 2015 Apr 28;6:6933
pubmed: 25917746
J Mater Chem B. 2014 Apr 28;2(16):2282-2289
pubmed: 32261716
J Pharm Pharm Sci. 2007;10(3):388-404
pubmed: 17727802
Annu Rev Immunol. 1992;10:411-52
pubmed: 1590993
PLoS One. 2018 Dec 20;13(12):e0209386
pubmed: 30571704
Biomater Sci. 2017 Sep 26;5(10):2093-2105
pubmed: 28805830
Macromol Biosci. 2013 May;13(5):551-61
pubmed: 23420700
Vet Comp Orthop Traumatol. 2006;19(3):142-6
pubmed: 16971996
Biochim Biophys Acta. 1986 Sep 4;883(2):173-7
pubmed: 3091074
N Engl J Med. 2006 Feb 23;354(8):841-8
pubmed: 16495396
Biofabrication. 2016 Oct 07;8(4):045002
pubmed: 27716628
Osteoarthritis Cartilage. 2003 Aug;11(8):595-602
pubmed: 12880582
Cytokine. 2018 Jan;101:26-32
pubmed: 27623350
Rheumatol Int. 2006 May;26(7):641-54
pubmed: 16362367
PLoS One. 2010 Apr 26;5(4):e10088
pubmed: 20436665
Biorheology. 2002;39(1-2):237-46
pubmed: 12082286
Biol Pharm Bull. 2007 Feb;30(2):237-41
pubmed: 17268058
Osteoarthritis Cartilage. 2016 Oct;24(10):1769-1775
pubmed: 27216281
Tissue Eng Part C Methods. 2012 Jun;18(6):444-52
pubmed: 22195986
PLoS One. 2016 Mar 01;11(3):e0149876
pubmed: 26930594
Acta Biomater. 2010 Jan;6(1):39-47
pubmed: 19660580
Adv Mater. 2013 Sep 25;25(36):5011-28
pubmed: 24038336
Trends Biotechnol. 2016 May;34(5):394-407
pubmed: 26867787
J Lab Autom. 2015 Aug;20(4):354-64
pubmed: 25720597
J Mater Chem B. 2013 Nov 7;1(41):5675-5685
pubmed: 32261191
J Pharm Sci. 2008 Jun;97(6):2041-4
pubmed: 17847072